Skip to Main Content

Administering bespoke CAR-T cell therapies from Bristol Myers Squibb or Gilead Sciences provides greater benefit than currently used treatments for certain patients with B-cell lymphoma, according to results from two randomized clinical trials released Thursday.

In the Bristol study, treatment with its CAR-T Breyanzi improved so-called event-free survival by 65% compared to standard chemotherapy and stem cell transplant.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment